uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology. Karolinska Inst, Clin Epidemiol Unit, Dept Med, Stockholm, Sweden..
Karolinska Inst, Clin Epidemiol Unit, Dept Med, Stockholm, Sweden..
Skane Univ Hosp, Dept Oncol, Lund, Sweden..
Skane Univ Hosp, Dept Oncol, Lund, Sweden..
Show others and affiliations
2015 (English)In: Journal of cancer survivorship, ISSN 1932-2259, E-ISSN 1932-2267, Vol. 9, no 4, 599-609 p.Article in journal (Refereed) PublishedText
Abstract [en]

Purpose This study seeks to investigate the long-term public health burden of Hodgkin lymphoma (HL) in terms of work loss following contemporary treatment protocols and associations with established treatment complications and lymphoma relapse. Methods We identified 1,989 Swedish HL patients (1,082 with clinical information) aged 18-60 (median 33) years at diagnosis 1992-2009, and matched 1:4 to population comparators. Sick leave, disability pension (work loss), and comorbidity were retrieved through September 2013. Relative risks (RR) with 95 % confidence intervals (CI) were calculated using Poisson regression, and mean lost work days were estimated yearly during follow-up. Results The risk of annual work loss was elevated in HL survivors versus comparators up to the 15th year post-diagnosis (RR5th year 1.64, 95 % CI 1.46-1.84; RR10th year 1.33, 95 % CI 1.15-1.34; and RR15th year 1.30, 95 % CI 1.04-1.62). The risk remained elevated up to the 10th year after adjustment for secondary malignancies and cardiovascular disease (RR10th year 1.31, 95 % CI 1.13-1.52). Advanced-stage patients had more lost days than comparators (mean number(5th year) 66 versus 33, mean difference 34, 95 % CI 20-48) as did patients receiving 6-8 chemotherapy courses (62 versus 33, mean difference(5th year) 30, 95 % CI 17-43). Among patients in the first complete remission, a difference was still observed for advanced-stage (51 versus 33, mean difference(5th year) 19, 95 % CI 5-34) but not early-stage disease. Conclusions Advanced-stage HL survivors treated with full-dose chemotherapy were at increased risk of work loss, not only explained by relapse, secondary malignancies, or cardiovascular disease.

Place, publisher, year, edition, pages
2015. Vol. 9, no 4, 599-609 p.
Keyword [en]
Hodgkin lymphoma, Sick leave, Disability pension, Chemotherapy, Cancer survivorship, Work loss
National Category
Cancer and Oncology
URN: urn:nbn:se:uu:diva-268764DOI: 10.1007/s11764-015-0436-0ISI: 000364563500003PubMedID: 25689964OAI: oai:DiVA.org:uu-268764DiVA: diva2:882486
Swedish Cancer Society, CAN 2012/774Stockholm County Council, 20120169Swedish Society of MedicineSwedish Society for Medical Research (SSMF)

Correction in Journal of Cancer Survivorship December 2015, Volume 9, Issue 4, pp 610-611.

DOI: 10.1007/s11764-015-0464-9

Available from: 2015-12-15 Created: 2015-12-09 Last updated: 2016-01-26Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Glimelius, Ingrid
By organisation
Experimental and Clinical Oncology
In the same journal
Journal of cancer survivorship
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 58 hits
ReferencesLink to record
Permanent link

Direct link